BioMarin Pharmaceutical Inc. (BMRN) — RQD Stock Rating Cockpit
BioMarin Pharmaceutical Inc. (BMRN) carries a Roarable Rating of C+ (Hold) with 66/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
Decent core business (78% profit margin), though cash flow growth is moderate rather than explosive right now.
Big funds and company insiders are mostly holding steady without aggressive buying or panic selling.
Clean SEC fine-print check with low hidden accounting risk and favorable interest-rate weather.
2-of-3 JEV AI Jury Bullish on BMRN
6.0% ROIC with 77.7% gross margin and 6.51% FCF yield.
Altman-Z 5.57 and Piotroski 8/9 pass balance-sheet audit.
Put/Call 0.67x with 22/40 institutional & insider flow.
- ✓Clean SEC annual filing review with no major hidden accounting time-bombs.
- !Broader market pullbacks can still drag down strong stocks in the short run.
Today's Top 3 RQD Strong Buys & Whale Accumulation Setups (Live BMRN Tape Review)
- ✓Live breakdown of today’s highest-scoring RQD Green-Light breakouts
- ✓1 urgent Red-Light accounting trap to cut from your watchlist immediately
- ✓Bring any ticker to live Q&A—we run it through the 5-Pillar RQD Radar on screen
BMRN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +12.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on BMRN today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for BMRN. Explore sector supply chains on /butterfly.
BMRN Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDShould I buy, hold, or sell BMRN stock right now?
BioMarin Pharmaceutical Inc. (BMRN) currently earns a Roarable Rating of C+ (Hold — HOLD) with 66/100 RQD Confidence. Solid 78% profit margin (6% return on capital), mixed timing at 32x P/E—hold if owned, no rush to chase.
What is BMRN's 12-month price target and RQD AI Jury consensus?
BMRN's 12-month base price target is $59.56 (range $46.46 to $74.53), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.